Back to top

Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Adlai Nortye Ltd. Sponsored ADR. The associated price target remain...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Adlai Nortye Ltd. Sponsored ADR (ANL)